Ulotaront
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Ulotaront
- Molecular weight
- 183.28
- Structure (SMILES)
- CNC[C@@H]1OCCc2ccsc21
- sep 363856
- sep 856
- Sep-363856
- SEP-363856
- SEP-856
- ulotaront
- Ulotaront
- ulotaront [INN]
- ULOTARONT [USAN]
- ulotaront inn
- ulotaront usan
- CAS registry numbers
- 1310426-33-5
- ChEMBL ID
- CHEMBL4650337
- InChIKey
- ABDDQTDRAHXHOC-QMMMGPOBSA-N
- PubChem compound IDs
- 89532783
- FDA ingredient codes (UNII)
- 3K6270MG59
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ulotaront
- Type
- Synthetic organic
- Drug name stem
- -taront
- Action
- Agonist
- Action type
- Agonist
- Target
- 5-HT1A receptor
- Gene symbol
- HTR1A
- Protein identifier
- P08908
- Median affinity
- 5.64
- Affinity units
- pIC50
- Action
- Agonist
- Action type
- Agonist
- Target
- TA1 receptor
- Gene symbol
- TAAR1
- Protein identifier
- Q96RJ0
- Median affinity
- 6.85
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Serotonin 1a (5-HT1a) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1A
- Protein identifier
- P08908
- Mechanism
- Trace amine-associated receptor 1 agonist
- Action type
- Agonist
- Target
- Trace amine-associated receptor 1
- Protein identifier
- Q96RJ0
- Mechanism
- Serotonin 1a (5-HT1a) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1A
- Mechanism
- Trace amine-associated receptor 1 agonist
- Action type
- Agonist
- Target
- Trace amine-associated receptor 1
- Condition
- Anxiety Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001892
- Subject identifier
- D001008
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Schizophrenia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition
- Parkinson Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Narcolepsy
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0016158
- Subject identifier
- D009290
- Condition identifier
- EFO_1001892
- Condition identifier
- MONDO_0001942
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016158
- Condition identifier
- MONDO_0016158
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0021107
- Highest recorded phase
- 1
- Event
- escherichia sepsis
- Reports
- 2
- Reporting signal score
- 9.49152
- Event
- mental status changes
- Reports
- 3
- Reporting signal score
- 8.28377
- Event
- neutrophil toxic granulation present
- Reports
- 1
- Reporting signal score
- 7.00032
- Event
- substance-induced mood disorder
- Reports
- 1
- Reporting signal score
- 7.16061
- NCT01940159
- NCT01972711
- NCT01994473
- NCT02969382
- NCT02970929
- NCT03370640
- NCT04038957
- NCT04072354
- NCT04092686
- NCT04109950
- NCT04325737
- NCT04825860
- NCT04865835
- NCT05359081
- NCT05402111
- NCT05463770
- NCT05542264
- NCT05628103
- NCT05741528
- NCT05848700
- NCT05593029
- NCT05729373
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 21.26
- Calculated partition coefficient (ALogP)
- 1.58
- Calculated partition coefficient (XLogP)
- 0.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 12
- Molecular formula
- C9H13NOS
- Monoisotopic mass
- 183.07178521
- Natural product
- No
- Recorded assays
- 47
- Active assays
- 8
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (28)
- A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
- A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
- A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
- A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
- A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
- A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
- A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
- A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
In development for (6)
- Generalized anxiety disorder Phase 2
- Major depressive disorder Phase 2
- Narcolepsy Phase 1
- Narcolepsy-cataplexy syndrome Phase 1
- Parkinson disease Phase 1
- Schizophrenia Phase 3